dizziness; Headache; double vision; nausea; brain fog; malaise; neck pain; blurry vision; weight loss; gait difficulty; muscle weakness; fully vaccinated, received Moderna Jan & Feb2021. Received Pfizer booster 14Nov2021; fully vaccinated, received Moderna Jan & Feb2021. Received Pfizer booster 14Nov2021; booster; autoimmune disorders such as myasthenia gravis; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 14Nov2021 12:30 (Batch/Lot number: unknown) at the age of 72 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "afib" (unspecified if ongoing); "imbalance disorder" (unspecified if ongoing); "rheumatoid arthritis" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Moderna covid-19 vaccine (Dose 1), administration date: Jan2021, when the patient was 71 years old, for covid-19 immunization; Moderna covid-19 vaccine (dose 2), administration date: Feb2021, for Covid-19 Immunization. The following information was reported: OFF LABEL USE (disability, medically significant), INTERCHANGE OF VACCINE PRODUCTS (disability, medically significant) all with onset 14Nov2021 12:30, outcome "unknown" and all described as "fully vaccinated, received Moderna Jan & Feb2021. Received Pfizer booster 14Nov2021"; IMMUNISATION (disability, medically significant) with onset 14Nov2021 12:30, outcome "unknown", described as "booster"; MYASTHENIA GRAVIS (disability, medically significant) with onset 2021, outcome "not recovered", described as "autoimmune disorders such as myasthenia gravis"; DIZZINESS (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "dizziness"; HEADACHE (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "Headache"; DIPLOPIA (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "double vision"; NAUSEA (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "nausea"; FEELING ABNORMAL (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "brain fog"; MALAISE (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "malaise"; NECK PAIN (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "neck pain"; VISION BLURRED (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "blurry vision"; WEIGHT DECREASED (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "weight loss"; GAIT DISTURBANCE (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "gait difficulty"; MUSCULAR WEAKNESS (disability) with onset 16Nov2021 12:00, outcome "not recovered", described as "muscle weakness". The events "autoimmune disorders such as myasthenia gravis", "dizziness", "headache", "double vision", "nausea", "brain fog", "malaise", "neck pain", "blurry vision", "weight loss", "gait difficulty" and "muscle weakness" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (18Nov2021) negative, notes: Nasal Swab; (12Dec2021) negative, notes: Nasal Swab; (26Nov2021) negative, notes: Nasal Swab. Therapeutic measures were taken as a result of myasthenia gravis, dizziness, headache, diplopia, nausea, feeling abnormal, malaise, neck pain, vision blurred, weight decreased, gait disturbance, muscular weakness.  Patient had no receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient had received other medications the patient received within 2 weeks of vaccination Patient had treatment received for the adverse event was prednisone. Patient had no diagnosed with COVID-19 Prior to vaccination. Patient had been tested for COVID-19 Since the vaccination.  The lot number for bnt162b2 was not provided and will be requested during follow up.